Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
The Lancet Neurology,  Clinical Article

Farkkila M et al. – Oral lasmiditan seems to be safe and effective in the acute treatment of migraine. Further assessment in larger placebo–controlled and triptan–controlled trials are needed to assess the potential role of lasmiditan in acute migraine therapy.

Methods
  • In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo.
  • Study drug and placebo were supplied in identical numbered tablet packs.
  • The randomisation code was generated by an independent statistician.
  • Patients and investigators were masked to treatment allocation.
  • The primary endpoint was dose response for headache relief (moderate or severe becoming mild or none) at 2 h.
  • The primary analysis was done in the modified intention-to-treat population.

Results
  • Between July 8 2009, and Feb 18, 2010, 512 patients were randomly assigned to treatment, 391 of whom received treatment.
  • 86 patients received placebo (81 included in primary analysis) and 305 received lasmiditan (50 mg n=79, 100 mg n=81, 200 mg n=69, and 400 mg n=68 included in primary analysis).
  • There was a linear association between headache response rate at 2 h and lasmiditan dose (Cochran-Armitage test p<0.0001).
  • Every lasmiditan treatment dose significantly improved headache response at 2 h compared with placebo (lasmiditan 50 mg: difference 17.9%, 95% CI 3.9-32.1, p=0.022; 100 mg: 38.2%, 24.1-52.4, p<0.0001; 200 mg: 28.8%, 9.6-39.9, p=0.0018; 400 mg: 38.7%, 23.9-53.6, p<0.0001).
  • The proportion of patients with treatment-emergent adverse events increased with increasing doses (53/82 [65%], 59/82 [72%], 61/71 [86%], and 59/70 [84%] for lasmiditan 50, 100, 200, and 400 mg, respectively vs 19/86 [22%] for placebo).
  • Most adverse events were mild or moderate in intensity, with 16 of 82 (20%), 23 of 82 (28%), 28 of 71 (39%), and 31 of 70 (44%) of patients on lasmiditan 50, 100, 200, and 400 mg, respectively reporting a severe adverse event compared with five of 86 (6%) on placebo.
  • The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

1 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 11, 2014    Clinical Article

2 Short-term effects of a manual therapy protocol on pain, physical function, quality of sleep, depressive symptoms, and pressure sensitivity in women and men with fibromyalgia syndrome: A randomized controlled trial The Clinical Journal of Pain, June 9, 2014    Clinical Article

3 Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study Journal of Affective Disorders, June 16, 2014    Clinical Article

4 Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications BMJ, June 12, 2014    Clinical Article

5 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 19, 2014    Clinical Article

6 The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials Nutrition, Metabolism & Cardiovascular Diseases, March 27, 2014    Evidence Based Medicine    Review Article

7 Risk of myocardial infarction and stroke in bipolar disorder: A systematic review and exploratory meta-analysis Acta Psychiatrica Scandinavica, May 30, 2014    Evidence Based Medicine    Review Article

8 Impact of mindfulness-based cognitive therapy on health care utilization: a population-based controlled comparison Journal of Psychosomatic Research, June 26, 2014    Clinical Article

9 Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit Clinical Research in Cardiology, May 23, 2014    Clinical Article

10 Effect of dietary restriction on peripheral monoamines and anxiety symptoms in obese subjects with metabolic syndrome Psychoneuroendocrinology, June 24, 2014    Clinical Article

11 Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder Neuropsychopharmacology, June 2, 2014    Clinical Article

12 Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial European Neuropsychopharmacology, May 22, 2014    Clinical Article

13 The association of internet addiction symptoms with anxiety, depression and self-esteem among adolescents with attention-deficit/hyperactivity disorder Comprehensive Psychiatry, June 17, 2014    Clinical Article

14 The impact of anxious symptoms in the remission of depressive symptoms in a clinical trial for depression: Follow-up of six months Journal of Affective Disorders, June 10, 2014    Clinical Article

15 Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – A systematic review Psychiatry Research, June 18, 2014    Evidence Based Medicine    Review Article

16 Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder Journal of Affective Disorders, June 16, 2014    Evidence Based Medicine    Review Article

17 Changes in circulating leptin levels during acute stress and associations with craving in abstinent smokers: A preliminary investigation Psychoneuroendocrinology, June 20, 2014    Clinical Article

18 Individual mindfulness-based cognitive therapy (MBCT) and cognitive behavior therapy (CBT) for treating depressive symptoms in patients with diabetes: Results of a randomized controlled trial Diabetes Care, June 6, 2014    Clinical Article

19 Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass : a prospective, population-based study JAMA Psychiatry, June 13, 2014    Clinical Article

20 Self-relevant disgust and self-harm urges in patients with borderline personality disorder and depression: A pilot study with a newly designed psychological challenge PLOS ONE, June 27, 2014    Clinical Article

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close